Alacrita Establishes Powerful Regulatory Affairs Practice to Serve Life Science Companies and Investors
LONDON, October 3, 2011 /PRNewswire/ –
Alacrita, which is changing the face of life science consulting
[http://www.alacritaconsulting.com ], has established a powerful
transatlantic Regulatory Affairs Practice to provide auditing, regulatory
strategy and due diligence services to life science companies and investors.
The Practice has been formed to help pharmaceutical, biotechnology and
medtech clients overcome critical regulatory hurdles, devise effective
regulatory strategies and provide on-going, hands-on regulatory support,
including with regulatory applications. The team is also supporting
companies and investors conducting regulatory due diligence.
The Practice currently comprises nine seasoned professionals, all of
whom have their careers either working within regulatory agencies or
shepherding life science products through regulatory processes. They have
particular expertise in EU and US regulations and have many years’
experience of interacting with the competent authorities in these regions.
The group has broad and deep technological experience, covering biologics,
pharmaceuticals, generics, in vitro diagnostics and medical devices. By
pooling their collective experiences and expertise, the group represents a
formidable resource for any life science company needing to supplement its
in-house regulatory capability.
Nick Higgins, Corporate Development Director at Consort Medical plc and
an Alacrita client said “Alacrita’s transatlantic team of experts was able
to provide us with the specialist regulatory due diligence support we
required. The advice was clear, well supported and enabled us to make an
informed decision on a potentially complex issue”.
Professor Anthony Dayan
[http://www.alacritaconsulting.com/board/profile.htm?id=AnthonyDayan ], a
member of Alacrita’s Advisory Board, expert in toxicology and Emeritus
Professor of Toxicology at the University of London, said “Alacrita’s team
has broad practical experience and deep knowledge of both the science and
regulations, allowing it to effectively assess toxicological risk. It has
the capacity and capability to work across a range of regulatory scenarios
within the life science industries”.
“Each consultant has been selected on the basis of their track record of
successfully applying creative solutions to critical regulatory issues” said
Partner at Alacrita. “Given the group’s practical, hands-on experience, we
go beyond just delivering GxP auditing services and, for example, actually
help clients with dossier filings to FDA and EMA”.
Alacrita’s regulatory affairs expertise spans small molecules and
biologics, sterile manufacturing, medtech and generics:
Small Molecules and Biologics
Whilst working in industry, Alacrita’s team took numerous pharma and
biologic products from Phase I through to marketing approval in both EU and
US. Alacrita’s US biologics consultant spent eight years at FDA/CBER before
moving into industry (Baxter, Medarex, Chiron) where she spent 20 years
implementing innovative regulatory and quality strategies for timely product
Alacrita’s European team includes a Qualified Person who specializes in
biologics, biotech products and sterile products. He has broad experience in
the manufacture and control of both terminally sterilised and aseptically
prepared sterile pharmaceuticals, including ophthalmic products, lyophilised
products, and creams and lotions, as well as most non-sterile dosage forms.
His US counterpart spent five years as a Microbiology Reviewer in the FDA’s
Office of Generic Drugs and after a 35 year career is a highly qualified and
well regarded problem solver of microbiology contamination issues.
Alacrita’s medtech regulatory specialists have deep experience in the
development, manufacturing, quality systems and regulatory affairs of
medical devices and in vitro diagnostics. In medical devices, Alacrita’s
consultant has acted as a senior representative for several well-known
Quality Certification Bodies (Notified Bodies) implementing consulting,
training and auditing assignments worldwide. His diagnostics colleague has
over ten years tenure as Head of a Medical and IVD Notified Body, having
secured the first IVD Notified Body status in the UK for Underwriters
Laboratories Inc. To date, they have completed over 300 medical device and
in vitro diagnostics audits.
Generics and Biosimilars
Alacrita’s generics consultant has over 15 years’ experience in
pharmaceutical regulatory affairs, pharmacovigilance and as a pharmacist.
She has extensive experience in generic pharmaceuticals where she has been
responsible for both strategic management and operational implementation.
She also works on projects involving pharmaceuticals, medical devices and
herbal medicines for a client base in the EU, USA and Canada.
More information about Alacrita’s pharma consulting
[http://www.alacritaconsulting.com/services ] services can be found at its
About Alacrita Consulting
Alacrita is rapidly growing consultancy that provides tailored, value
added solutions to clients in the pharmaceutical, biotechnology and life
Alacrita applies its real-world expertise and experience to rapidly
assess and understand the challenges faced by its clients and to develop
solutions that exactly meet their needs. This blueprint is then used to
access the Alacrita consultants best suited to deliver projects on time and
Alacrita provides its clients with access to consultants who combine
extensive international industry experience (strategic, technical and
commercial), broad functional capabilities and a track record of success
across the life science sector.
In addition, Alacrita’s network of more than 50 consultants with “hands
on” management experience allows it to solve client resourcing needs at
critical times in their corporate development.
Since inception, Alacrita and its network have completed successful
consulting projects for big pharma, biotech companies, life science
investors, government bodies and charities.
For further information, please contact: Anthony Walker
[http://www.linkedin.com/profile/view?id=5122905&trk=tyah ] or Rob Johnson